Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHair loss reported before and after starting Wegovy is real, but it is almost certainly not the semaglutide itself causing it. The most common culprit is telogen effluvium — a temporary shedding triggered by rapid weight loss and calorie reduction, not by the medicine directly. Most people who experience it see their hair recover within a few months, without stopping treatment. These are prescription-only medicines; a GPhC-registered prescriber reviews whether they are suitable for you before any treatment begins. Our Wegovy overview covers the broader picture of how semaglutide works and what to expect.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A question our prescribers hear most weeks is some version of: "I've read that Wegovy causes hair loss, will I go bald?" The short answer is no, and the longer answer is that most of what people are describing when they show before-and-after photos of thinning hair is telogen effluvium, a well-characterised shedding pattern that follows any period of significant physical stress on the body. Rapid weight loss, restricted calorie intake and the metabolic shift that accompanies both are classic triggers.
Here is what happens physiologically. Hair follicles cycle through growth, transition and resting phases. A sudden physiological stressor pushes a larger proportion of hairs simultaneously into the resting (telogen) phase. Six to twelve weeks later, those hairs shed at once. The result looks alarming (more hair on the pillow, more in the shower drain) but the follicles themselves remain intact. Growth resumes once the body stabilises. The NHS patient information on semaglutide describes alopecia as an uncommon listed side effect of Wegovy, but the shedding pattern most people photograph and post before-and-after comparisons of is driven by the weight-loss process, not a pharmacological action of semaglutide on follicle biology.
That distinction matters because it changes the response. Stopping the medicine is unlikely to help if telogen effluvium is the cause, and will simply halt progress on the underlying treatment.
People eating significantly less tend to get less protein, iron, zinc and biotin than they did before, especially in the early weeks of treatment, when nausea and reduced appetite are most noticeable. Hair is a non-essential tissue from the body's perspective: when nutrients are scarce, follicles are deprioritised. That is why the before-and-after picture people describe (fuller hair pre-treatment, visibly thinner hair two to three months in) maps so closely onto the period of steepest calorie deficit.
The practical implication is that protein adequacy matters more during treatment, not less. Aiming to keep protein intake reasonable (lean meat, fish, eggs, dairy, pulses) helps preserve lean muscle mass and supports hair-follicle nutrition simultaneously. If you are concerned about specific deficiencies, a blood test via your GP can check ferritin, iron and thyroid function, all of which independently affect hair cycling. Our page on hair loss and Wegovy goes into the nutritional angle in more depth.
Significant shedding typically peaks around the three-month mark and begins to resolve as the rate of weight loss moderates and nutritional intake stabilises. For a closer look at what to expect as things settle, our guide to hair loss after Wegovy covers how the before-and-after trajectory tends to unfold and what meaningful regrowth looks like over time. That timeline is consistent with what the clinical literature describes for post-weight-loss telogen effluvium generally.
Not every hair change during treatment is telogen effluvium, and not all of it is benign. Seek medical advice (from your GP or the prescribing team) if you notice patchy loss in defined areas (which can indicate alopecia areata, an autoimmune condition), hair that breaks rather than falls from the root, a receding hairline progressing faster than expected, or shedding that continues beyond nine months without any sign of slowing.
Some medical conditions that affect hair (thyroid disorders, anaemia, hormonal changes) can coincide with, or be unmasked by, starting a weight-loss programme. A blood test is a reasonable first step. If you are already experiencing significant shedding and want to know how semaglutide's side-effect profile is monitored, the MHRA Yellow Card scheme allows both patients and healthcare professionals to report suspected side effects directly. That reporting genuinely informs post-marketing safety surveillance for medicines like Wegovy.
On the timing question (how quickly side effects appear and how long they typically last) our page covering how long Wegovy side effects take to resolve gives a realistic picture, and our full side-effects overview covers the broader GI and systemic profile alongside the hair-related changes. If you are still in the early weeks of treatment and wondering when shedding might start, the timeline for when Wegovy side effects typically begin may be more relevant to where you are right now.
Our prescribers discuss suitability and side effects, including hair changes, as part of every consultation. If you have questions before committing to treatment, starting a free consultation is the place to raise them, no obligation, same-day review by a real clinician.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.